Quest Diagnostics reported a solid QQ1 2025 performance characterized by healthy revenue growth and stable profitability, underpinned by continued demand for core diagnostic testing services. Revenue reached $2.652 billion, up 12.1% year over year and 1.2% quarter over quarter, with a gross profit of $863 million and a gross margin of 32.54%. Operating income was $346 million, yielding an operating margin of 13.05%, and net income totaled $220 million for the quarter, delivering a net margin of 8.30% and EPS of $1.97 (diluted $1.94). The result supports a positive trajectory on volume and mix, while investments in technology and pathology services, as well as scale benefits, contributed to EBITDA of $488 million (EBITDA margin ~18.4%).